The BCL2 inhibitor venetoclax is approved in the United States for only a subset of patients with refractory chronic lymphocytic leukemia. However, in light of data presented at the American Society of Hematology 2017 Annual Meeting, clinicians are thinking ahead to administering the drug more broadly—in combinations and as a first-line therapy—for other patients with the disease.
http://ift.tt/2GW7uOi
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου